Toll Free: 1-888-928-9744

Contraception - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Contraception - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Contraception - Pipeline Review, H1 2015', provides an overview of the Contraception's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Contraception
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Contraception and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Contraception pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Contraception
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Contraception Overview 9 Therapeutics Development 10 Pipeline Products for Contraception - Overview 10 Pipeline Products for Contraception - Comparative Analysis 11 Contraception - Therapeutics under Development by Companies 12 Contraception - Therapeutics under Investigation by Universities/Institutes 14 Contraception - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Contraception - Products under Development by Companies 19 Contraception - Products under Investigation by Universities/Institutes 21 Contraception - Companies Involved in Therapeutics Development 22 Actavis plc 22 Agile Therapeutics, Inc. 23 ANI Pharmaceuticals, Inc. 24 Antares Pharma, Inc. 25 Evofem, Inc. 26 Hydra Biosciences, Inc. 27 Intas Pharmaceuticals Ltd. 28 Ligand Pharmaceuticals, Inc. 29 Merck & Co., Inc. 30 Orbis Biosciences, Inc. 31 Pantarhei Bioscience BV 32 Teva Pharmaceutical Industries Limited 33 Contraception - Therapeutics Assessment 34 Assessment by Monotherapy Products 34 Assessment by Combination Products 35 Assessment by Target 36 Assessment by Mechanism of Action 38 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Drug Profiles 44 (ethinyl estradiol + levonorgestrel) - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 (ethinylestradiol + levonorgestrel) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 (nestorone + estradiol) - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 (prasterone + estradiol + progesterone) - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 AG-200 ER - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 AG-200 SP - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Amphora - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 esterol - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 etonogestrel - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 EVE-106 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 levonorgestrel - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 LJ-102 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 MK-8342B - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Monoclonal Antibody Conjugates for Contraception - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 norethindrone - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 S-003296 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 S-0101255 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Small Molecule 1 for Fertility Control - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Small Molecule 2 for Fertility Control - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Small Molecule to Modulate Progesterone Receptor for Fertility Control - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Small Molecules to Block CatSper1 Ion Channel for Contraception - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Synthetic Peptides for Contraception - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 tanaproget - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 ulipristal acetate - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Contraception - Recent Pipeline Updates 73 Contraception - Dormant Projects 77 Contraception - Discontinued Products 79 Contraception - Product Development Milestones 80 Featured News & Press Releases 80 Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora 80 Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch 80 Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study 80 Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla 81 Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion 82 Jul 04, 2014: Teva Receives CHMP Positive Opinion for Seasonique Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries 82 Jun 26, 2014: Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date 83 Jun 20, 2014: Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion Transdermal Delivery Device 83 Jul 24, 2013: Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora® Non-hormonal Contraceptive Gel 84 Jul 23, 2013: Enrollment Completed for Evofem's 3,200-subject Global Trial of Amphora Non-hormonal Contraceptive Gel 84 Appendix 86 Methodology 86 Coverage 86 Secondary Research 86 Primary Research 86 Expert Panel Validation 86 Contact Us 86 Disclaimer 87
List of Tables
Number of Products under Development for Contraception, H1 2015 10 Number of Products under Development for Contraception - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Investigation by Universities/Institutes, H1 2015 14 Comparative Analysis by Late Stage Development, H1 2015 15 Comparative Analysis by Clinical Stage Development, H1 2015 16 Comparative Analysis by Early Stage Development, H1 2015 17 Comparative Analysis by Unknown Stage Development, H1 2015 18 Products under Development by Companies, H1 2015 19 Products under Development by Companies, H1 2015 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2015 21 Contraception - Pipeline by Actavis plc, H1 2015 22 Contraception - Pipeline by Agile Therapeutics, Inc., H1 2015 23 Contraception - Pipeline by ANI Pharmaceuticals, Inc., H1 2015 24 Contraception - Pipeline by Antares Pharma, Inc., H1 2015 25 Contraception - Pipeline by Evofem, Inc., H1 2015 26 Contraception - Pipeline by Hydra Biosciences, Inc., H1 2015 27 Contraception - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 28 Contraception - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 29 Contraception - Pipeline by Merck & Co., Inc., H1 2015 30 Contraception - Pipeline by Orbis Biosciences, Inc., H1 2015 31 Contraception - Pipeline by Pantarhei Bioscience BV, H1 2015 32 Contraception - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 33 Assessment by Monotherapy Products, H1 2015 34 Assessment by Combination Products, H1 2015 35 Number of Products by Stage and Target, H1 2015 37 Number of Products by Stage and Mechanism of Action, H1 2015 39 Number of Products by Stage and Route of Administration, H1 2015 41 Number of Products by Stage and Molecule Type, H1 2015 43 Contraception Therapeutics - Recent Pipeline Updates, H1 2015 73 Contraception - Dormant Projects, H1 2015 77 Contraception - Dormant Projects (Contd..1), H1 2015 78 Contraception - Discontinued Products, H1 2015 79



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify